Testing SR604 for congenital factor VII deficiency
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 65 years old.
- You must have been diagnosed with congenital factor VII deficiency, with factor VII activity less than 10%.
- You must have had at least 2 treated bleeding episodes in the 3 months before joining.
- You must not have any active bleeding symptoms before starting the study drug.
- You must be willing to use highly effective birth control (if you could become pregnant or get someone pregnant) throughout the study.
- You cannot have other bleeding disorders, a history of blood clots, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Factor VII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.